- 作者：Khushnooma Y. Italia ; Farah J. Jijina ; Rashid Merchant ; Sangeeta Panjwani ; Anita H. Nadkarni ; Pratibha M. Sawant ; Sona B. Nair ; Kanjaksha Ghosh ; Roshan B. Colah
- 关键词：β ; thalassemia ; Hydroxyurea ; XmnI polymorphism ; α ; – ; thalassemia ; γ ; mRNA expression
- 刊名：Clinica Chimica Acta
- 出版年：2009
- 出版时间：3 September 2009
- 年：2009
- 卷：407
- 期：1-2
- 页码：10-15
- 全文大小：225 K
BackgroundThe clinical and hematological response to hydroxyurea was evaluated in β thalassemia patients in western India with variable clinical severity and correlated with genetic factors.Materials and methods
Seventy-nine patients-[38-β thalassemia intermedia-(group I), 41-β thalassemia major-(group II)] on hydroxyurea therapy were followed-up for 20–24 months.
Results
Among the frequently transfused patients in group I, 58 % became transfusion independent and 16 % showed a 50 % reduction in transfusions after therapy which correlated with a higher mean fold increase in HbF and γ mRNA expression levels. Forty-one percent of patients in group I had associated α-thalassemia and 72.7 % were XmnI (+/+). β thalassemia chromosomes among the responders of group I (41 % ) were linked to haplotype (− + + − + + − − +) as against haplotype (+ − − − − − − − +) being more common among the non-responders. Response was not linked to the β thalassemia mutations. Thirty-two percent of group II patients showed a 50 % reduction in their transfusion requirements after therapy which also correlated with a higher mean fold increase in HbF and γ mRNA expression levels. A significant decrease in serum ferritin was seen in both groups. 19 % of patients could not tolerate the drug.
Conclusions
In group I, clinical response to hydroxyurea was better in patients with α–thalassemia, XmnI (+/+) and a higher mean fold increase in γ mRNA expression. In group II, only one-third of patients showed a partial response.